BioMarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings Call Transcript Summary
BioMarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings Call Transcript Summary
Enzyme Therapies portfolio contributed $509 million in revenue, a 27% increase from the previous year primarily due to increased ALDURAZYME revenue.The following is a summary of the BioMarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings Call Transcript:
以下是BioMarin製藥公司（BMRN）2024年第三季度業績會文本摘要：
Financial Performance:
金融業績：
BioMarin Pharmaceutical Inc. reported a record Q3 2024 revenue of $746 million, a 28% increase compared to the same period in 2023.
VOXZOGO generated $190 million in revenue for Q3, up 54% year-over-year.
Enzyme Therapies portfolio contributed $509 million in revenue, a 27% increase from the previous year primarily due to increased ALDURAZYME revenue.
Non-GAAP operating margin reached 28% in Q3, showcasing significant profitability expansion.
BioMarin raised its full-year 2024 revenue guidance to between $2.79 billion and $2.825 billion, indicating a 16% growth at the midpoint year-over-year.
BioMarin製藥公司報告2024年第三季度營業收入達到74600萬美元，較2023年同期增長28%。
VOXZOGO在第三季度實現19000萬美元的營業收入，同比增長54%。
酶療法組合在營收中貢獻了50900萬美元，較上一年增長27%，主要是由於ALDURAZYME營收增加。
第三季度的非通用會計淨利潤率達到28%，展示了顯著的盈利能力擴張。
BioMarin將其2024年全年營業收入指導提高至27.9億至28.25億美元，中間值同比增長16%。
Business Progress:
業務進展：
BioMarin is focusing on new corporate strategy pillars: innovation, growth, and value commitment.
Significant advancements in skeletal conditions, enzyme therapies, and ROCTAVIAN units.
Introduction of key leadership roles in the company, promising stronger execution of new strategies.
Continued global launch and market expansion of VOXZOGO for achondroplasia, plus development and investment in enzyme therapy.
BioMarin正專注於新的企業戰略支柱：創新、增長和價值承諾。
骨骼條件、酶療法和ROCTAVIAN單位方面取得顯著進展。
公司引入關鍵領導職務，承諾更強執行新策略。
持續全球推出和市場擴張VOXZOGO用於骨發育不全，以及在酶療法的開發和投資。
Opportunities:
機會：
The company's future growth is supported by VOXZOGO's market expansion and the global reach of their skeletal conditions and enzyme therapies.
Potential growth in achondroplasia market with plans for further penetration and protection of intellectual property.
Expectation to rapidly grow the enzyme therapy portfolio through focused initiatives, geographical expansions, and patient adherence programs.
公司未來增長得到VOXZOGO市場擴張以及其骨骼病和酶療法在全球範圍內的影響力支持。
在骨發育不全市場潛在增長，計劃進一步滲透和保護知識產權。
預計通過專注倡議、地理擴張和患者依從計劃迅速增長酶療法產品組合。
Risks:
風險：
Potential competitive threats to VOXZOGO from new entrants in the achondroplasia treatment market.
Reliance on the continued performance and market expansion of flagship products like VOXZOGO and enzyme therapies.
VOXZOGO在無軟骨發育症治療市場面臨來自新進入者的潛在競爭威脅。
依賴於VOXZOGO和酶療法等旗艦產品持續表現和市場擴張。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
